Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:
Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York
Saad Z. Usmani, MD, MBA, FACP
Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina
Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; and Thomas G. Martin, MD discuss the use of BCMA-targeted agents in relapsed/refractory multiple myeloma in an on-demand webcast, from Clinical Care Options (CCO)
Patient-friendly resource on myelodysplastic syndromes from Clinical Care Options (CCO)
Download this short summary slideset on myelodysplastic syndromes to help diagnose and manage your patients, from Clinical Care Options (CCO).
Expert commentary on the pharmacist’s role in caring for CAR T-cell therapy recipients, from Clinical Care Options (CCO)